Gemini Therapeutics (GMTX) Competitors

$67.03 +2.96 (+4.62%)

As of 05/20/2026

GMTX vs. AXSM, ARWR, ELAN, RDY, and ABVX

Should you buy Gemini Therapeutics stock or one of its competitors? MarketBeat compares Gemini Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gemini Therapeutics include Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Gemini Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Gemini Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Gemini Therapeutics' return on equity of -38.78% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Gemini Therapeutics	N/A	-38.78%	-35.88%

In the previous week, Axsome Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Axsome Therapeutics and 0 mentions for Gemini Therapeutics. Axsome Therapeutics' average media sentiment score of 0.02 beat Gemini Therapeutics' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Axsome Therapeutics	Neutral
Gemini Therapeutics	Neutral

Axsome Therapeutics currently has a consensus target price of $251.26, suggesting a potential upside of 7.54%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.83	-$183.17M	-$3.73	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Axsome Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Summary

Axsome Therapeutics beats Gemini Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 16.23%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Arrowhead Pharmaceuticals had 7 more articles in the media than Gemini Therapeutics. MarketBeat recorded 7 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.41 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Arrowhead Pharmaceuticals	Neutral

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Arrowhead Pharmaceuticals	$829.45M	12.83	-$1.63M	-$2.15	N/A

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Elanco Animal Health?

Gemini Therapeutics (NASDAQ:GMTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, Elanco Animal Health had 9 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for Elanco Animal Health and 0 mentions for Gemini Therapeutics. Elanco Animal Health's average media sentiment score of 0.59 beat Gemini Therapeutics' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Elanco Animal Health	Positive

Gemini Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Elanco Animal Health	-4.95%	7.42%	3.66%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gemini Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Elanco Animal Health	$4.72B	2.26	-$232M	-$0.50	N/A

Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 32.36%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Summary

Elanco Animal Health beats Gemini Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Gemini Therapeutics (NASDAQ:GMTX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Dr. Reddy's Laboratories has a consensus target price of $16.90, suggesting a potential upside of 24.95%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts clearly believe Dr. Reddy's Laboratories is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Dr. Reddy's Laboratories and 0 mentions for Gemini Therapeutics. Dr. Reddy's Laboratories' average media sentiment score of 0.14 beat Gemini Therapeutics' score of 0.00 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Dr. Reddy's Laboratories	Neutral

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Gemini Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%

Dr. Reddy's Laboratories has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Dr. Reddy's Laboratories	$3.58B	3.15	$484.20M	$0.58	23.32

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats Gemini Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, Abivax had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Abivax and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.00 beat Abivax's score of -0.09 indicating that Gemini Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Abivax	Neutral
Gemini Therapeutics	Neutral

Gemini Therapeutics' return on equity of -38.78% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Abivax presently has a consensus target price of $137.15, indicating a potential upside of 10.58%. Given Abivax's stronger consensus rating and higher probable upside, equities analysts clearly believe Abivax is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

47.9% of Abivax shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abivax has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

Summary

Abivax and Gemini Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.90B	$935.12M	$6.35B	$12.29B
Dividend Yield	N/A	4.84%	2.79%	5.33%
P/E Ratio	-67.03	1.44	21.08	25.34
Price / Sales	N/A	117.33	528.17	80.04
Price / Cash	N/A	20.07	44.13	56.16
Price / Book	23.19	7.54	10.00	7.01
Net Income	-$71.87M	-$3.91M	$3.55B	$335.27M
7 Day Performance	-3.83%	0.08%	1.99%	1.28%
1 Month Performance	-2.97%	73.26%	-0.87%	0.16%
1 Year Performance	37.10%	122.80%	36.38%	34.54%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$67.03 +4.6%	N/A	+33.8%	$2.90B	N/A	N/A	30	High Trading Volume
AXSM Axsome Therapeutics	2.3259 of 5 stars	$235.32 +5.0%	$251.26 +6.8%	+120.9%	$11.53B	$638.50M	N/A	380
ARWR Arrowhead Pharmaceuticals	2.1466 of 5 stars	$77.88 -1.5%	$87.80 +12.7%	+393.4%	$11.13B	$829.45M	N/A	400
ELAN Elanco Animal Health	4.6217 of 5 stars	$21.84 +1.9%	$28.20 +29.1%	+68.6%	$10.70B	$4.72B	N/A	9,400
RDY Dr. Reddy's Laboratories	3.6476 of 5 stars	$12.97 +4.1%	$16.90 +30.4%	-5.7%	$10.40B	$3.58B	22.35	27,811	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. AXSM, ARWR, ELAN, RDY, and ABVX

How does Gemini Therapeutics compare to Axsome Therapeutics?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Gemini Therapeutics compare to Elanco Animal Health?

Summary

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Gemini Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. AXSM, ARWR, ELAN, RDY, and ABVX

How does Gemini Therapeutics compare to Axsome Therapeutics?

Is AXSM or GMTX more profitable?

Does the media refer more to AXSM or GMTX?

Do analysts prefer AXSM or GMTX?

Which has better earnings and valuation, AXSM or GMTX?

Do institutionals and insiders have more ownership in AXSM or GMTX?

Which has more volatility and risk, AXSM or GMTX?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Which has more risk & volatility, GMTX or ARWR?

Do insiders and institutionals hold more shares of GMTX or ARWR?

Is GMTX or ARWR more profitable?

Do analysts prefer GMTX or ARWR?

Does the media favor GMTX or ARWR?

Which has stronger valuation and earnings, GMTX or ARWR?

Summary

How does Gemini Therapeutics compare to Elanco Animal Health?

Which has more risk & volatility, GMTX or ELAN?

Does the media prefer GMTX or ELAN?

Is GMTX or ELAN more profitable?

Do institutionals & insiders have more ownership in GMTX or ELAN?

Which has higher earnings and valuation, GMTX or ELAN?

Do analysts prefer GMTX or ELAN?

Summary

How does Gemini Therapeutics compare to Dr. Reddy's Laboratories?

Do analysts recommend GMTX or RDY?

Does the media prefer GMTX or RDY?

Is GMTX or RDY more profitable?

Which has preferable earnings and valuation, GMTX or RDY?

Do institutionals & insiders have more ownership in GMTX or RDY?

Which has more volatility & risk, GMTX or RDY?

Summary

How does Gemini Therapeutics compare to Abivax?

Which has stronger earnings & valuation, ABVX or GMTX?

Does the media refer more to ABVX or GMTX?

Is ABVX or GMTX more profitable?

Do analysts prefer ABVX or GMTX?

Do insiders and institutionals believe in ABVX or GMTX?

Which has more risk & volatility, ABVX or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools